Amarogentin

CAS# 21018-84-8

Amarogentin

Catalog No. BCN2661----Order now to get a substantial discount!

Product Name & Size Price Stock
Amarogentin: 5mg $63 In Stock
Amarogentin: 10mg Please Inquire In Stock
Amarogentin: 20mg Please Inquire Please Inquire
Amarogentin: 50mg Please Inquire Please Inquire
Amarogentin: 100mg Please Inquire Please Inquire
Amarogentin: 200mg Please Inquire Please Inquire
Amarogentin: 500mg Please Inquire Please Inquire
Amarogentin: 1000mg Please Inquire Please Inquire

Quality Control of Amarogentin

Number of papers citing our products

Chemical structure

Amarogentin

3D structure

Chemical Properties of Amarogentin

Cas No. 21018-84-8 SDF Download SDF
PubChem ID 115149 Appearance Yellowish powder
Formula C29H30O13 M.Wt 586.54
Type of Compound Iridoids Storage Desiccate at -20°C
Solubility DMSO : 130 mg/mL (221.64 mM; Need ultrasonic)
Chemical Name [(2S,3R,4S,5S,6R)-2-[[(3S,4R,4aS)-4-ethenyl-8-oxo-4,4a,5,6-tetrahydro-3H-pyrano[3,4-c]pyran-3-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl] 2,4-dihydroxy-6-(3-hydroxyphenyl)benzoate
SMILES C=CC1C2CCOC(=O)C2=COC1OC3C(C(C(C(O3)CO)O)O)OC(=O)C4=C(C=C(C=C4C5=CC(=CC=C5)O)O)O
Standard InChIKey DBOVHQOUSDWAPQ-WTONXPSSSA-N
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Amarogentin

1 Swertia sp.

Biological Activity of Amarogentin

Description1. Amarogentin incorporated in liposomes or niosomes may have clinical application in the treatment of leishmaniasis. 2. Amarogentin plays cemopreventive/therapeutic role during liver carcinogenesis through modulation of cell cycle and apoptosis. 3. Amarogentin prevents platelet activation through the inhibition of PLC γ2-PKC cascade and MAPK pathway, it may offer therapeutic potential for preventing or treating thromboembolic disorders.
TargetsCOX | PKC | MAPK | p53 | p21 | Caspase | Bcl-2/Bax | PARP | c-Myc

Amarogentin Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Amarogentin Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Amarogentin

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.7049 mL 8.5246 mL 17.0491 mL 34.0983 mL 42.6228 mL
5 mM 0.341 mL 1.7049 mL 3.4098 mL 6.8197 mL 8.5246 mL
10 mM 0.1705 mL 0.8525 mL 1.7049 mL 3.4098 mL 4.2623 mL
50 mM 0.0341 mL 0.1705 mL 0.341 mL 0.682 mL 0.8525 mL
100 mM 0.017 mL 0.0852 mL 0.1705 mL 0.341 mL 0.4262 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Amarogentin

Prevention of liver carcinogenesis by amarogentin through modulation of G1/S cell cycle check point and induction of apoptosis.[Pubmed:22948180]

Carcinogenesis. 2012 Dec;33(12):2424-31.

Amarogentin, a secoiridoid glycoside, is an active component of the medicinal plant Swertia chirata. In this study, chemopreventive and chemotherapeutic actions of Amarogentin were evaluated in a carbon tetrachloride (CCl(4))/N-nitrosodiethylamine (NDEA)-induced liver carcinogenesis mouse model system during continuous and posttreatment schedule. Better survival, no toxicity and increased body weight were noted in Amarogentin-treated mice. Reduction in proliferation and increase in apoptosis frequency were evident in Amarogentin-treated groups. In carcinogen control group moderate dysplasia, severe dysplasia and hepatocellular carcinoma were evident at 10th, 20th and 30th week, respectively. Amarogentin was found to prevent progression of liver carcinogenesis at mild dysplastic stage. Exposure to CCl(4)/NDEA resulted in upregulation of ppRb807/811, cyclinD1 and cdc25A at 10th week and additional activation of cMyc and mdm2 along with downregulation of LIMD1, p53 and p21 at 20th week. This was followed by activation of ppRb567 and downregulation of Rbsp3 at 30th week. Prevention of carcinogenesis by Amarogentin in both groups might be due to cumulative upregulation of LIMD1, RBSP3, p16 and downregulation of cdc25A at 10th week along with activation of p53 and p21 and downregulation of ppRb807/811 and ppRb567 at 20th week, followed by downregulation of cyclinD1, cMyc and mdm2 at 30th week. During carcinogenesis reduction of apoptosis was evident since 20th week. However, Amarogentin treatment could significantly induce apoptosis through upregulation of the Bax-Bcl2 ratio, activation of caspase-3 and poly ADP ribose polymerase cleavage. This is the first report of chemopreventive/therapeutic role of Amarogentin during liver carcinogenesis through modulation of cell cycle and apoptosis.

Amarogentin, a secoiridoid glycoside, abrogates platelet activation through PLC gamma 2-PKC and MAPK pathways.[Pubmed:24868545]

Biomed Res Int. 2014;2014:728019.

Amarogentin, an active principle of Gentiana lutea, possess antitumorigenic, antidiabetic, and antioxidative properties. Activation of platelets is associated with intravascular thrombosis and cardiovascular diseases. The present study examined the effects of Amarogentin on platelet activation. Amarogentin treatment (15~60 muM) inhibited platelet aggregation induced by collagen, but not thrombin, arachidonic acid, and U46619. Amarogentin inhibited collagen-induced phosphorylation of phospholipase C (PLC) gamma2, protein kinase C (PKC), and mitogen-activated protein kinases (MAPKs). It also inhibits in vivo thrombus formation in mice. In addition, neither the guanylate cyclase inhibitor ODQ nor the adenylate cyclase inhibitor SQ22536 affected the Amarogentin-mediated inhibition of platelet aggregation, which suggests that Amarogentin does not regulate the levels of cyclic AMP and cyclic GMP. In conclusion, Amarogentin prevents platelet activation through the inhibition of PLC gamma2-PKC cascade and MAPK pathway. Our findings suggest that Amarogentin may offer therapeutic potential for preventing or treating thromboembolic disorders.

Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms.[Pubmed:10590280]

J Antimicrob Chemother. 1999 Dec;44(6):791-4.

The antileishmanial property of Amarogentin, a secoiridoid glycoside isolated from the Indian medicinal plant Swertia chirata, was examined in a hamster model of experimental leishmaniasis. The therapeutic efficacy of Amarogentin was evaluated in free and two different vesicular forms, liposomes and niosomes. The Amarogentin in both liposomal and niosomal forms was found to be a more active leishmanicidal agent than the free Amarogentin; and the niosomal form was found to be more efficacious than the liposomal form at the same membrane microviscosity level. Toxicity studies involving blood pathology, histological staining of tissues and specific enzyme levels related to normal liver function showed no toxicity. Hence, Amarogentin incorporated in liposomes or niosomes may have clinical application in the treatment of leishmaniasis.

Description

Amarogentin is a secoiridoid glycoside that is mainly extracted from Swertia and Gentiana roots. Amarogentin exhibits many biological effects, including anti-oxidative, anti-tumour, and anti-diabetic activities. Amarogentin exerts hepatoprotective and immunomodulatory effects. Amarogentin promotes apoptosis, arrests G2/M cell cycle and downregulates of PI3K/Akt/mTOR signalling pathways. Amarogentin exerts beneficial vasculo-metabolic effect by activating AMPK.

Keywords:

Amarogentin,21018-84-8,Natural Products, buy Amarogentin , Amarogentin supplier , purchase Amarogentin , Amarogentin cost , Amarogentin manufacturer , order Amarogentin , high purity Amarogentin

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: